RHYTHM PHARMACEUTICALS, INC. Repayments of Long-Term Debt
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Repayments of Long-Term Debt of $11.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2026-06-30 was $6.91M, a 59.44% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2026-03-31 was $4.29M, a 7.09% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2025-12-31 was $5.40M, a 41.81% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2025-09-30 was $5.57M, a 66.97% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2025 was $19.92M, a 54.40% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2024 was $12.90M, a 74.37% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2023 was $7.40M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $11.20M 10-Q · filed 2026-08-04 | $16.59M derived: sum of 3 quarters · filed 2026-08-04 | $22.16M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.29M 10-Q · filed 2026-05-05 | $9.69M derived: sum of 2 quarters · filed 2026-05-05 | $15.26M derived: sum of 3 quarters · filed 2026-05-05 | $19.59M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.97M derived: sum of 2 quarters · filed 2026-02-26 | $15.30M derived: sum of 3 quarters · filed 2026-08-04 | $19.92M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.90M derived: sum of 2 quarters · filed 2026-08-04 | $14.52M 10-Q · filed 2025-11-04 | $18.32M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $4.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $8.95M 10-Q · filed 2026-08-04 | $12.76M derived: sum of 3 quarters · filed 2026-08-04 | $16.09M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.62M 10-Q · filed 2026-05-05 | $8.42M derived: sum of 2 quarters · filed 2026-05-05 | $11.76M derived: sum of 3 quarters · filed 2026-05-05 | $14.73M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.14M derived: sum of 2 quarters · filed 2026-02-26 | $10.12M derived: sum of 3 quarters · filed 2026-02-26 | $12.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.31M derived: sum of 2 quarters · filed 2025-11-04 | $9.09M 10-Q · filed 2025-11-04 | $11.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $5.76M 10-Q · filed 2025-08-05 | $8.33M derived: sum of 3 quarters · filed 2026-02-26 | $10.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.78M 10-Q · filed 2025-05-07 | $5.36M derived: sum of 2 quarters · filed 2026-02-26 | $7.52M derived: sum of 3 quarters · filed 2026-02-26 | $8.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.74M derived: sum of 2 quarters · filed 2026-02-26 | $6.05M derived: sum of 3 quarters · filed 2026-02-26 | $7.40M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.47M derived: sum of 2 quarters · filed 2024-11-06 | $4.82M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.66M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $1.35M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |